- ISIN
- US4781601046
- CUSIP
- 478160104
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO Date
- Sep 24, 1944
Highlights
- Market Cap
- $558.46B
- Enterprise Value
- $571.69B
- EPS (TTM)
- $8.65
- PE Ratio
- 26.41
- PEG Ratio
- 0.88
- Total Revenue (TTM)
- $96.36B
- Gross Profit (TTM)
- $66.60B
- EBITDA (TTM)
- $31.62B
- Year Range
- $149.74 - $251.71
- Target Price
- $249.27
- ROA (TTM)
- 10.47%
- ROE (TTM)
- 25.92%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
JNJ Performance Chart
Johnson & Johnson (JNJ) is up 11.6% since the beginning of the year. At $228 per share, JNJ is trading 9.3% below its 52-week high of $252. Investors who bought $1,000 worth of JNJ shares 5 years ago would now be looking at an investment worth $1,623.
Loading charts...
Returns By Period
Johnson & Johnson (JNJ) has returned 11.58% so far this year and 56.28% over the past 12 months. Over the last ten years, JNJ has returned 9.93% per year, falling short of the S&P 500 Index benchmark, which averaged 13.54% annually.
Johnson & Johnson
- 1D
- -2.48%
- 1M
- -0.87%
- YTD
- 11.58%
- 6M
- 11.90%
- 1Y
- 56.28%
- 3Y*
- 14.93%
- 5Y*
- 10.17%
- 10Y*
- 9.93%
Benchmark (S&P 500 Index)
- 1D
- 0.00%
- 1M
- -0.34%
- YTD
- 8.39%
- 6M
- 8.57%
- 1Y
- 24.33%
- 3Y*
- 18.94%
- 5Y*
- 12.24%
- 10Y*
- 13.54%
JNJ Monthly Returns History
Based on dividend-adjusted daily data since Jan 2, 1970, JNJ's average daily return is +0.06%, while the average monthly return is +1.12%. At this rate, an investment would double in approximately 5.2 years.
Historically, 58% of months were positive and 42% were negative. The best month was Feb 1975 with a return of +21.2%, while the worst month was May 1984 at -17.4%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 9 months.
On a daily basis, JNJ closed higher 49% of trading days. The best single day was Oct 13, 2008 with a return of +12.2%, while the worst single day was Oct 19, 1987 at -18.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.81% | 9.90% | -1.61% | -5.97% | -1.40% | 1.36% | 11.58% | ||||||
| 2025 | 5.21% | 9.33% | 0.50% | -5.75% | 0.15% | -1.58% | 7.85% | 8.33% | 4.66% | 1.86% | 10.25% | 0.01% | 47.48% |
| 2024 | 1.38% | 2.33% | -1.98% | -8.60% | 2.26% | -0.35% | 8.00% | 5.87% | -2.29% | -1.36% | -2.26% | -6.70% | -4.81% |
| 2023 | -7.49% | -5.54% | 1.14% | 5.61% | -4.56% | 6.75% | 1.21% | -2.79% | -3.67% | -4.76% | 5.10% | 1.34% | -8.58% |
| 2022 | 0.71% | -3.87% | 7.69% | 1.82% | 0.12% | -1.13% | -1.68% | -6.93% | 1.25% | 6.49% | 2.98% | -0.76% | 5.97% |
| 2021 | 3.65% | -2.26% | 3.72% | -0.99% | 4.66% | -2.66% | 4.53% | 1.14% | -6.72% | 0.85% | -3.64% | 9.71% | 11.44% |
Benchmark Metrics
Johnson & Johnson has an annualized alpha of 7.62%, beta of 0.71, and R2 of 0.29 versus S&P 500 Index. Calculated based on daily prices since January 02, 1970.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (84.39%) than losses (64.19%) - typical of diversified or defensive assets.
- R2 of 0.29 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 7.62%
- Beta
- 0.71
- R²
- 0.29
- Upside Capture
- 84.39%
- Downside Capture
- 64.19%
Return for Risk
Risk / Return Rank
JNJ ranks 95 for risk / return — in the top 95% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Johnson & Johnson (JNJ) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| JNJ | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.31 | ||
| Sortino ratioReturn per unit of downside risk | +2.01 | ||
| Omega ratioGain probability vs. loss probability | 1.58 | 1.35 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 5.07 | 2.66 | +2.41 |
| Martin ratioReturn relative to average drawdown | 14.87 | 11.86 | +3.00 |
Dividends
Dividend History
Johnson & Johnson provided a 2.29% dividend yield over the last twelve months, with an annual payout of $5.24 per share. The company has been increasing its dividends for 25 consecutive years, earning it the status of a dividend aristocrat.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $5.24 | $5.14 | $4.91 | $4.70 | $4.45 | $4.19 | $3.98 | $3.75 | $3.54 | $3.32 | $3.15 | $2.95 |
Dividend yield | 2.29% | 2.48% | 3.40% | 3.00% | 2.52% | 2.45% | 2.53% | 2.57% | 2.74% | 2.38% | 2.73% | 2.87% |
Monthly Dividends
The table displays the monthly dividend distributions for Johnson & Johnson. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $1.30 | $0.00 | $0.00 | $1.34 | $0.00 | $2.64 | ||||||
| 2025 | $0.00 | $1.24 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $5.14 |
| 2024 | $0.00 | $1.19 | $0.00 | $0.00 | $1.24 | $0.00 | $0.00 | $1.24 | $0.00 | $0.00 | $1.24 | $0.00 | $4.91 |
| 2023 | $0.00 | $1.13 | $0.00 | $0.00 | $1.19 | $0.00 | $0.00 | $1.19 | $0.00 | $0.00 | $1.19 | $0.00 | $4.70 |
| 2022 | $0.00 | $1.06 | $0.00 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $0.00 | $1.13 | $0.00 | $4.45 |
| 2021 | $0.00 | $1.01 | $0.00 | $0.00 | $1.06 | $0.00 | $0.00 | $1.06 | $0.00 | $0.00 | $1.06 | $0.00 | $4.19 |
Dividend Yield & Payout
Dividend Yield
Johnson & Johnson has a dividend yield of 2.29%, which is quite average when compared to the overall market.
Payout Ratio
Johnson & Johnson has a payout ratio of 59.52%, which is quite average when compared to the overall market. This suggests that Johnson & Johnson strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Johnson & Johnson. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Johnson & Johnson was 50.67%, occurring on Apr 25, 1977. Recovery took 1034 trading sessions.
The current Johnson & Johnson drawdown is 7.59%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
1977 bear market1977 | -50.67%Apr 1977 | 4y 5mo | 4y 1mo | 8y 7moNov 1972 - May 1981 |
1984 bear market1984 | -42.53%Jul 1984 | 1y 2mo | 10mo 19d | 2y 1moMay 1983 - Jun 1985 |
Black Monday1987 | -38.35%Oct 1987 | 1mo 24d | 1y 7mo | 1y 8moAug 1987 - May 1989 |
1970 bear market1970 | -37.58%May 1970 | 4mo 24d | 7mo 16d | 1y 5dJan 1970 - Jan 1971 |
1993 bear market1993 | -36.52%Aug 1993 | 1y 7mo | 1y 2mo | 2y 9moJan 1992 - Oct 1994 |
Drawdown Indicators
| JNJ | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -50.67% | -56.78% | +6.11% |
Max Drawdown (1Y)Largest decline over 1 year | -10.96% | -9.10% | -1.86% |
Max Drawdown (3Y)Largest decline over 3 years | -15.95% | -18.90% | +2.95% |
Max Drawdown (5Y)Largest decline over 5 years | -18.41% | -25.43% | +7.02% |
Max Drawdown (10Y)Largest decline over 10 years | -27.37% | -33.92% | +6.55% |
Current DrawdownCurrent decline from peak | -7.59% | -2.49% | -5.10% |
Average DrawdownAverage peak-to-trough decline | -11.90% | -10.72% | -1.18% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.73% | 2.03% | +1.70% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Johnson & Johnson over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Johnson & Johnson is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for JNJ, comparing it with other companies in the Drug Manufacturers - General industry. Currently, JNJ has a P/E ratio of 26.4. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for JNJ compared to other companies in the Drug Manufacturers - General industry. JNJ currently has a PEG ratio of 0.9. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for JNJ relative to other companies in the Drug Manufacturers - General industry. Currently, JNJ has a P/S ratio of 5.8. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for JNJ in comparison with other companies in the Drug Manufacturers - General industry. Currently, JNJ has a P/B value of 6.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with JNJ
Add Johnson & Johnson to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with JNJ